COA-tested research peptides · Same-day UK dispatch on orders before 3pm · Tracked delivery
Veritide is an independent affiliate site. We earn commission from UK SARMs on qualifying orders placed through our links — at no extra cost to you. Read our disclosure
Research hub · Source-linked, claim-free
Industry news, how to actually read a certificate of analysis, what each test result does and doesn't prove, what the published literature reports, and the myths that circulate anyway.
Educational reference only. Research use only — not medical advice, and not for human or veterinary use.
What's changing in research-peptide supply, quality expectations and UK regulation.
Unlicensed chemical reference materials hold no MHRA marketing authorisation. That means no approved indication, no product information leaflet and no permitted health claims — supply is legitimate only where the material is sold, labelled and used as laboratory research material.
Human Medicines Regulations 2012 ›Buyers increasingly ask for batch-specific analytical data rather than a generic specification sheet. A COA that names the batch, the method and the testing laboratory is now the baseline for any credible supplier.
ICH Q2(R2) analytical validation ›Two vials can both read 99% by HPLC and still differ. Deletion sequences, truncations, trifluoroacetate counter-ion content and residual water all sit outside a headline purity figure, which is why method detail on the COA matters.
USP general chapter <1503> peptide impurities ›Four things appear on a credible peptide COA. Here is what each one measures — and what it cannot tell you.
HPLC
Reverse-phase high-performance liquid chromatography
Separates the target peptide from related impurities and reports the main peak as a percentage of total peak area. Look for the column, gradient, wavelength and the actual chromatogram — a bare number with no trace is not a result.
Look for: ≥ 98% main peak with a printed chromatogram and named method
MS
Mass spectrometry (ESI-MS / MALDI-TOF)
Confirms identity by measuring molecular mass against the theoretical mass of the sequence. Purity cannot be established by MS alone; it answers 'is this the right molecule?', not 'how much else is in there?'.
Look for: Observed mass within a few Da of theoretical, with the spectrum shown
Appearance & solubility
Visual and reconstitution checks
Lyophilised peptide should be a white to off-white cake or powder. Discolouration, oily residue or a collapsed cake can indicate moisture ingress or heat exposure in transit or storage.
Look for: White lyophilised cake, sealed vial, intact flip-off seal
Water & counter-ion
Karl Fischer / TFA content
Net peptide content is lower than gross vial weight once water and counter-ion are accounted for. This is the single most common reason a stated milligram figure and an assay figure disagree.
Look for: Reported water content and counter-ion, or a stated net peptide content
Summaries below describe mechanisms and models reported in peer-reviewed literature. They are not claims about outcomes in humans or animals, and nothing here is medical advice or guidance on use.
Published work characterises retatrutide as an agonist at the GIP, GLP-1 and glucagon receptors. Interest in the research literature centres on that combined receptor pharmacology relative to single- and dual-agonist reference peptides.
Search the literature on PubMed ›The available literature is largely preclinical: rodent and in-vitro models examining fibroblast migration and angiogenic signalling. There are no completed large-scale human trials, and no regulator has authorised it for any indication.
Search the literature on PubMed ›Research describes actin-binding activity and cell-migration effects in cell culture and animal models. Reported findings are model-specific and are not evidence of any outcome in humans.
Search the literature on PubMed ›Studied in fibroblast and skin-model systems for collagen and matrix gene expression. Most published data are in-vitro, and cosmetic-science literature is distinct from clinical evidence.
Search the literature on PubMed ›Six claims repeated constantly in peptide forums, and what the analytics actually say.
“99% purity” means the vial is 99% peptide
Reality — Purity is a chromatographic ratio of peak areas, not a mass balance of the vial. Water, counter-ion and excipients are separate figures. A 99% HPLC result with 12% water content is still 99% pure by that method.
A COA is a COA
Reality — A certificate is only meaningful when it names the batch, the analytical method and the laboratory that ran it. A PDF with no batch number cannot be tied to the vial in front of you — always request the batch-specific document.
Third-party testing and in-house testing are interchangeable
Reality — In-house data can be entirely valid, but it is not independent. Third-party analysis is a separate laboratory with no commercial interest in the result. Reputable suppliers are explicit about which one you are reading.
Research peptides are regulated like supplements
Reality — They are neither medicines nor food supplements. They are unlicensed reference materials for in-vitro laboratory research, with no approved use, and they must not be administered to humans or animals.
Preclinical findings predict human outcomes
Reality — Cell-culture and rodent data establish mechanism and plausibility, not efficacy or safety in people. Most compounds with promising preclinical signals never demonstrate a clinical benefit.
Cheaper vials are the same product
Reality — Price differences usually track synthesis scale, purification passes and testing depth. The absence of an impurity profile is a cost saving that has been passed to you as unknown risk.
Every peptide line is released against batch analytical documentation. Ask for the certificate covering the exact vial you receive.
